Insights from experimental studies into allodynia and its treatment

Current Pain and Headache Reports

Volumn 10, Issue 3, 2006, Pages 225-230

  Oshinsky, Michael L ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BRADYKININ; CANNABINOID DERIVATIVE; DIHYDROERGOTAMINE; HISTAMINE; INDOMETACIN; KETOROLAC; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NITRIC OXIDE; PLACEBO; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; SEROTONIN; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SUMATRIPTAN; TRIPTAN DERIVATIVE;

ALLODYNIA; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE MODEL; EXPERIMENTAL STUDY; HEADACHE; HUMAN; INTRACTABLE PAIN; MEDICAL RESEARCH; MIGRAINE; NERVOUS SYSTEM; NOCICEPTION; NOCICEPTIVE RECEPTOR; NONHUMAN; PAIN THRESHOLD; PATHOGENESIS; PROTEIN SYNTHESIS INHIBITION; REVIEW; SENSITIZATION; TRIGEMINAL NUCLEUS;

ANALGESICS; ANIMALS; DRUG RESISTANCE; HUMANS; HYPERALGESIA; MIGRAINE DISORDERS;

EID: 33745300803     PISSN: 15313433     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11916-006-0050-y     Document Type: Review

References (67)

1. Treede R, Kenshalo DR, Gracely RH, Jones AK: The cortical representation of pain. Pain 1999, 79105-111.
2. Merskey H: Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy. Pain Suppl 1986, 3:S1-226.
3. Burstein R, Cutrer MF, Yarnitsky D: The development of cutaneous allodynia during a migraine attack: clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000, 123:1703-1709.
4. Burstein R: Deconstructing migraine headache into peripheral and central sensitization. Pain 2001, 89:107-110.
5. Reuter U, Bolay H, Jansen-Olesen I, et al.: Delayed inflammation in rat meninges: implications for migraine pathophysiology. Brain 2001, 124:2490-2502.
6. Moskowitz MA, Macfarlane R: Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc Brain Metab Rev 1993, 5:159-177.
7. Treede R, Meyer RA, Raja SN, Campbell JN: Peripheral and central mechanisms of cutaneous hyperalgesia. Prog Neurobiol 1992, 38:397-421.
8. Raja SN, Campbell JN, Meyer RA: Evidence for different mechanisms of primary and secondary hyperalgesia following heat injury to the glabrous skin. Brain 1984, 107:1179-1188.
9. Meyer RA, Campbell JN: Myelinated nociceptive afferents account for the hyperalgesia that follows a burn to the hand. Science 1981, 213:1527-1529.
10. Moalem G, Tracey DJ: Immune and inflammatory mechanisms in neuropathic pain. Brain Res Brain Res Rev 2005, [Epub ahead of print].
11. Christoph T, Reissmuller E, Schiene K, et al.: Antiallodynic effects of NMDA glycine(B) antagonists in neuropathic pain: possible peripheral mechanisms. Brain Res 2005, 1048:218-227.
12. Coutaux A, Adam F, Le Bars D, Willer J: Hyperalgesia and allodynia: Peripheral mechanisms. Joint Bone Spine 2005, 72:359-371.
13. Vanegas H, Schaible HG: Descending control of persistent pain: inhibitory or facilitatory? Brain Res Brain Res Rev 2004, 46:295-309.
14. Witting N, Svensson P, Jensen TS: Differential recruitment of endogenous pain inhibitory systems in neuropathic pain patients. Pain 2003, 103:75-81.
15. Mason P: Deconstructing endogenous pain modulations. J. Neurophysiol 2005, 94:1659-1663.
16. Cervero F, Laird JM, Garcia-Nicas E: Secondary hyperalgesia and presynaptic inhibition: an update. Eur J Pain 2003, 7:345-351.
17. Cervero F, Laird JM: Mechanisms of allodynia: interactions between sensitive mechanoreceptors and nociceptors. Neuroreport 1996, 7:526-528.
18. Woolf CJ, Thompson SW: The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation: implications for the treatment of post-injury pain hypersensitivity states. Pain 1991, 44:293-299.
19. Liveing E: On Megrim, Sick-Headache, and Some Allied Disorders. Nijmegen: Arts & Boeve; 1873.
20. Wolff HG: Headache and Other Pain. Oxford: Oxford University Press; 1963.
21. Selby G, Lance JW: Observations on 500 cases of migraine and allied vascular headache. J Neurol Neurosurg Psychiatry 1960, 23:23-32.
22. Tfelt Hansen P, Lous I, Olesen J: Prevalence and significance of muscle tenderness during common migraine attacks. Headache 1981, 21:49-54.
23. Drummond PD: Scalp tenderness and sensitivity to pain in migraine and tension headache. Headache 1987, 27:45-50.
24. Jensen K: Extracranial blood flow, pain and tenderness in migraine: clinical and experimental studies. Acta Neurol Scand Suppl 1993, 147:1-27.
25. Strassman AM, Raymond SA, Burstein R: Sensitization of meningeal sensory neurons and the origin of headaches. Nature 1996, 384:560-564.
26. Burstein R, Yamamura H, Malick A, Strassman AM: Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol 1998, 79:964-982.
27. Burstein R, Falkowsky O, Borsook D, Strassman A: Distinct lateral and medial projections of the spinohypothalamic tract of the rat. J Comp Neurol 1996, 373:549-574.
28. Yamamura H, Malick A, Chamberlin NL, Burstein R: Cardiovascular and neuronal responses to head stimulation reflect central sensitization and cutaneous allodynia in a rat model of migraine. J Neurophysiol 1999, 81:479-493.
29. Malick A, Strassman RM, Burstein R: Trigeminohypothalamic and reticulohypothalamic tract neurons in the upper cervical spinal cord and caudal medulla of the rat. J Neurophysiol 2000, 84:2078-2112.
30. Malick A, Burstein R: Peripheral and central sensitization during migraine. Funct Neurol 2000, 15 (suppl 3):28-35.
31. Burstein R, Yarnitsky D, Goor-Aryeh I, et al.: An association between migraine and cutaneous allodynia. Ann Neurol 2000, 47:614-624.
32. Burstein R, Jakubowski M: Migraine with and without allodynia: new sub-classification of migraine. In The Classification and Diagnosis of Headache Disorders. Edited by Olsen J. New York: Oxford University Press; 2005:3-11.
33. Luo J, Piovesan E, Oshinsky ML: Neurochemistry of sensitization in the trigeminal nucleus caudalis [Abstract]. Headache 2003, 43.
34. Burstein R, Jakubowski M: Unitary hypothesis for multiple triggers of the pain and strain of migraine. J Comp Neurol 2005, 493:9-14.
35. Burstein R, Levy D, Jakubowski M: Effects of sensitization of trigeminovascular neurons to triptan therapy during migraine. Rev Neurol (Paris) 2005, 161:658-660.
36. Oshinsky ML, Piovesan EJ, Pozo-Rosich P: Intravenous administration of the serotonin (5HT) 1B/D receptor agonist zolmitriptan blocks central sensitization in the trigeminal nucleus caudalis. Neurology 2004, 62:A533-A534.
37. Jakubowski M, Levy D, Goor-Aryeh I, et al.: Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache 2005, 45:850-861.
38. Burstein R, Jakubowski M: Implications of multimechanism therapy: when to treat? Neurology 2005, 10(suppl 2):S16-S20.
39. Olesen J, Diener HC, Schoenen J, Hettiarachchi J: No effect of eletriptan administration during the aura phase of migraine. Eur J Neurol 2004, 11:671-677.
40. Dowson A: Can oral 311C90, a novel 5-HT1D agonist, prevent migraine headache when taken during an aura? Eur Neurol 1996, 36(suppl 2):28-31.
41. Bates D, Ashford E, Dawson R, et al.: Subcutaneous sumatriptan during the migraine aura. Sumatriptan Aura Study Group. Neurology 1994, 9:1587-1592.
42. Brandes JL, Kudrow D, Cady R, et al.: Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing. Cephalalgia 2005, 44:735-742.
43. Ji RR, Kohno T, Moore KA, Woolf CJ: Central sensitization and LTP: Do pain and memory share similar mechanisms? Trends Neurosci 2003, 26:696-705.
44. Cervero F, Laird JM: Visceral pain. Lancet 1999, 353:2145-2148.
45. Potrebic S, Ahn AH, Skinner K, et al.: Peptidergic nociceptors of both trigeminal and dorsal root ganglia express serotonin 1D receptors: implications for the selective antimigraine action of triptans. J Neurosci 2003, 23:10988-10997.
46. Bartsch T, Knight YE, Goadsby PJ: Activation of 5-HT(1B/1D) receptor in the periaqueductal gray inhibits nociception. Ann Neurol 2004, 56:371-381.
47. Raskin NH: Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology 1986, 36:995-997.
48. Pozo-Rosich P, Oshinsky ML: Effects of dihydroergotamine (DHE) on central sensitization of neurons in the trigeminal nucleus caudalis [Abstract S19.003]. Program and abstracts of the American Academy of Neurology 57th Annual Meeting. Miami Beach, FL: April 9-16, 2005.
49. Silberstein SD, Young WB, Hopkins MM, et al.: DHE-45 for migraine with cutaneous allodynia: a pilot study. Program and abstracts of the American Academy of Neurology 57th Annual Meeting. Miami Beach, FL: April 9-16, 2005.
50. Jakubowski M, Levy D, Goor-Aryeh I, et al.: Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache 2005, 45:850-861.
51. Durrenberger PF, Facer P, Casula MA, et al.: Prostanoid receptor EP1 and COX-2 in injured human nerves and a rat model of nerve injury: a time-course study. BMC Neurol 2006, 6:1.
52. Bingham S, Beswick PJ, Bountra C, et al.: The cyclooxygenase-2 inhibitor GW406381X [2-(4-ethoxyphenyl)-3-[4-(methylsulfonyl) phenyl]-pyrazolo[1,5-b]pyridazine] is effective in animal models of neuropathic pain and central sensitization. J Pharmacol Exp Ther 2005, 312:1161-1169.
53. Fox A, Medhurst S, Courade JP, et al.: Anti-hyperalgesic activity of the COX-2 inhibitor lumiracoxib in a model of bone cancer pain in the rat. Pain 2004, 107:33-40.
54. Lui PW, Lee CH: Pre-emptive effects of intrathecal cyclooxygenase inhibitor or nitric oxide synthase inhibitor on thermal hypersensitivity following peripheral nerve injury. Life Sci 2004, 75:2527-2538.
55. Lee YW, Park KA, Lee WT: Effects of MK-801 and morphine on spinal C-Fos expression during the development of neuropathic pain. Yonsei Med J 2002, 43:370-376.
56. Medvedev IO, Malyshkin AA, Belozertseva IV, et al.: Effects of low-affinity NMDA receptor channel blockers in two rat models of chronic pain. Neuropharmacology 2004, 47:175-183.
57. You HJ, Chen J, Morch CD, Arendt-Nielsen L: Differential effect of peripheral glutamate (NMDA, non-NMDA) receptor antagonists on bee venom-induced spontaneous nociception and sensitization. Brain Res Bull 2002, 58:561-567.
58. Berry JD, Petersen KL: A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster. Neurology 2005, 65:444-447.
59. Blackburn-Munro G, Erichsen HK: Antiepileptics and the treatment of neuropathic pain: evidence from animal models. Curr Pharm Des 2005, 11:2961-2976.
60. Jang Y, Kim ES, Park SS, et al.: The suppressive effects of oxcarbazepine on mechanical and cold allodynia in a rat model of neuropathic pain. Anesth Analg 2005, 101:800-806.
61. Idanpaan-Heikkila JJ, Guilbaud G: Pharmacological studies on a rat model of trigeminal neuropathic pain: baclofen, but not carbamazepine, morphine or tricyclic antidepressants, attenuates the allodynia-like behaviour. Pain 1999, 79:281-290.
62. Lampl C, Yazdi K, Roper C: Amitriptyline in the prophylaxis of central post-stroke pain: preliminary results of 39 patients in a placebo-controlled, long-term study. Stroke 2002, 33:3030-3032.
63. Bomholt SF, Mikkelsen JD, Blackburn-Munro G: Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent, and neuropathic pain. Neuropharmacology 2005, 48:252-263.
64. Hartrick CT: Increased production of nitric oxide stimulated by interferon-gamma from peripheral blood monocytes in patients with complex regional pain syndrome. Neurosci Lett 2002, 323:75-77.
65. Dogrul A, Gul H, Yildiz O, et al.: Cannabinoids blocks tactile allodynia in diabetic mice without attenuation of its antinociceptive effect. Neurosci Lett 2004, 368:82-86.
66. Rukwied R, Watkinson A, McGlone F, Dvorak M: Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain 2003, 102:283-288.
67. Bridges D, Ahmad K, Rice AS: The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol 2001, 133:586-594.